KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Total Debt (2017 - 2023)

Historic Total Debt for Bionano Genomics (BNGO) over the last 7 years, with Q3 2023 value amounting to $10.0 million.

  • Bionano Genomics' Total Debt rose 749.22% to $10.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $10.0 million, marking a year-over-year increase of 749.22%. This contributed to the annual value of $9.4 million for FY2022, which is N/A changed from last year.
  • According to the latest figures from Q3 2023, Bionano Genomics' Total Debt is $10.0 million, which was up 749.22% from $10.0 million recorded in Q2 2023.
  • In the past 5 years, Bionano Genomics' Total Debt ranged from a high of $20.1 million in Q4 2019 and a low of $9.2 million during Q2 2022
  • Moreover, its 5-year median value for Total Debt was $15.7 million (2020), whereas its average is $14.3 million.
  • As far as peak fluctuations go, Bionano Genomics' Total Debt surged by 12244.01% in 2019, and later tumbled by 1909.49% in 2020.
  • Bionano Genomics' Total Debt (Quarter) stood at $20.1 million in 2019, then fell by 18.72% to $16.3 million in 2020, then decreased by 8.94% to $14.9 million in 2021, then plummeted by 36.89% to $9.4 million in 2022, then grew by 6.59% to $10.0 million in 2023.
  • Its Total Debt stands at $10.0 million for Q3 2023, versus $10.0 million for Q2 2023 and $9.5 million for Q1 2023.